ADARx Pharmaceuticals, Inc. ADRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 746.00K | 2.14M | 1.62M | 1.62M | 208.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 746.00K | 2.14M | 1.62M | 1.62M | 208.00K |
| Cost of Revenue | 24.74M | 23.58M | 20.77M | 20.77M | 17.07M |
| Gross Profit | -23.99M | -21.44M | -19.15M | -19.15M | -16.87M |
| SG&A Expenses | 5.90M | 5.62M | 5.52M | 5.52M | 4.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.64M | 29.20M | 26.30M | 26.30M | 21.33M |
| Operating Income | -29.89M | -27.06M | -24.68M | -24.68M | -21.12M |
| Income Before Tax | -25.76M | -22.67M | -19.72M | -19.72M | -18.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.76M | -22.67M | -19.72M | -19.72M | -18.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.76M | -22.67M | -19.72M | -19.72M | -18.09M |
| EBIT | -29.89M | -27.06M | -24.68M | -24.68M | -21.12M |
| EBITDA | -29.58M | -26.76M | -24.39M | -24.39M | -20.89M |
| EPS Basic | -2.27 | -2.00 | -1.73 | -1.73 | -1.59 |
| Normalized Basic EPS | -1.42 | -1.25 | -1.08 | -1.08 | -1.00 |
| EPS Diluted | -2.27 | -2.00 | -1.73 | -1.73 | -1.59 |
| Normalized Diluted EPS | -1.42 | -1.25 | -1.08 | -1.08 | -1.00 |
| Average Basic Shares Outstanding | 11.32M | 11.32M | 11.38M | 11.38M | 11.36M |
| Average Diluted Shares Outstanding | 11.32M | 11.32M | 11.38M | 11.38M | 11.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |